Apoptosis and cell proliferation in the development of gastric carcinomas:: Associations with c-myc and p53 protein expression

被引:40
作者
Ishii, HH
Gobé, GC
Pan, WS
Yoneyama, J
Ebihara, Y
机构
[1] Tokyo Med Univ, Dept Pathol 2, Shinjuku Ku, Tokyo 1600023, Japan
[2] Univ Queensland, Mayne Med Sch, Dept Pathol, Brisbane, Qld, Australia
关键词
adenocarcinoma; Ki-67; oncogenes; tumor suppressor genes;
D O I
10.1046/j.1440-1746.2002.02805.x
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
Background and Aim: Patients with gastric carcinomas have a poor prognosis and low survival rates. The aim of the present paper was to characterize cellular and molecular properties to provide insight into aspects of tumor progression in early compared with advanced gastric cancers. Methods: One hundred and nine graded gastric carcinomas (early or advanced stage, undifferentiated or differentiated type) with paired non-cancer tissue were studied to define the correlation between apoptosis (morphology, terminal deoxyribonucleotidyl transferase-mediated dUTP-digoxigenin nick end-labeling), cell proliferation (Ki-67 expression, morphology) and expression and localization of two proteins frequently having altered expression in cancers, namely p53 and c-myc. Results: Overall, apoptosis was lower in early stage, differentiated and undifferentiated gastric carcinomas compared with advanced-stage cancers. Cell proliferation was comparatively high in all stages. There was a high level of p53 positivity in all stages. Only the early- and advanced-stage undifferentiated cancers that were p53 positive had a significantly higher level of apoptosis (P< 0.05). Cell proliferation was significantly greater (P < 0.05) only in the early undifferentiated cancers that had either c-myc or p53-positivity. Conclusions: The results indicate that low apoptosis and high cell proliferation combine to drive gastric cancer development. The molecular controls for high cell proliferation of the early stage undifferentiated gastric cancers involve overexpression of both p53 and c-myc. Overexpression of p53 may also control cancer development in that its expression is associated with higher levels of apoptosis in early and late-stage undifferentiated, cancers. (C) 2002 Blackwell Publishing Asia Pty Ltd.
引用
收藏
页码:966 / 972
页数:7
相关论文
共 44 条
[1]
ARENDS MJ, 1994, AM J PATHOL, V144, P1045
[2]
APOPTOTIC CELL-DEATH INDUCED BY C-MYC IS INHIBITED BY BCL-2 [J].
BISSONNETTE, RP ;
ECHEVERRI, F ;
MAHBOUBI, A ;
GREEN, DR .
NATURE, 1992, 359 (6395) :552-554
[3]
Primary central nervous system lymphomas in 72 immunocompetent patients pathologic findings and clinical correlations [J].
Camilleri-Broet, S ;
Martin, A ;
Moreau, A ;
Angonin, R ;
Hénin, D ;
Gontier, MF ;
Rousselet, MC ;
Caulet-Maugendre, S ;
Cuillière, P ;
Lefrancq, T ;
Mokhtari, K ;
Morcos, M ;
Broët, P ;
Kujas, N ;
Hauw, JJ ;
Desablens, B ;
Raphaël, M .
AMERICAN JOURNAL OF CLINICAL PATHOLOGY, 1998, 110 (05) :607-612
[4]
The Myc oncoprotein: a critical evaluation of transactivation and target gene regulation [J].
Cole, MD ;
McMahon, SB .
ONCOGENE, 1999, 18 (19) :2916-2924
[5]
ElenitobaJohnson KSJ, 1996, AM J CLIN PATHOL, V106, P728
[6]
INDUCTION OF APOPTOSIS IN FIBROBLASTS BY C-MYC PROTEIN [J].
EVAN, GI ;
WYLLIE, AH ;
GILBERT, CS ;
LITTLEWOOD, TD ;
LAND, H ;
BROOKS, M ;
WATERS, CM ;
PENN, LZ ;
HANCOCK, DC .
CELL, 1992, 69 (01) :119-128
[7]
Gobé G, 2000, J AM SOC NEPHROL, V11, P454, DOI 10.1681/ASN.V113454
[8]
IN-SITU DETECTION OF FRAGMENTED DNA (TUNEL ASSAY) FAILS TO DISCRIMINATE AMONG APOPTOSIS, NECROSIS, AND AUTOLYTIC CELL-DEATH - A CAUTIONARY NOTE [J].
GRASLKRAUPP, B ;
RUTTKAYNEDECKY, B ;
KOUDELKA, H ;
BUKOWSKA, K ;
BURSCH, W ;
SCHULTEHERMANN, R .
HEPATOLOGY, 1995, 21 (05) :1465-1468
[9]
Epstein-Barr virus infection is an early event in gastric carcinogenesis and is independent of bcl-2 expression and p53 accumulation [J].
Gulley, ML ;
Pulitzer, DR ;
Eagan, PA ;
Schneider, BG .
HUMAN PATHOLOGY, 1996, 27 (01) :20-27
[10]
Structure and function of the p53 tumor suppressor gene: Clues for rational cancer therapeutic strategies [J].
Harris, CC .
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 1996, 88 (20) :1442-1455